Screener / SEC EDGAR /CIK 0000914475 /10-K filed Feb 11, 2026, compared with Feb 10, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Neurocrine Biosciences Inc NBIX

Compare with peers Embed
The 10-K against last year's

127 changes: 39 added, 15 removed, 72 reworded, 1 quiet changes

10-K Feb 11, 2026 vs Feb 10, 2025

10-K 0000914475-26-000007 (Feb 11, 2026) vs 10-K 0000914475-25-000037 (Feb 10, 2025) Not compared: Legal Proceedings.

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

268 paragraphs · 31 new · 66 reworded · 9 gone · 10-K Feb 11, 2026 against Feb 10, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 175 · 48% changed Every version of it
For example, the Inflation Reduction Act of 2022, or the IRA, IRA provides for, among other things: (1) the Secretary of the HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare; (2) the redesign of the Medicare Part D prescription drug benefit to lower patient out-of-pocket costs and increase manufacturer liability; and (3) drug manufacturers to pay rebates on drugs whose prices increase greater than the rate of inflation. The IRA also extends enhanced subsidies Each year up to twenty (20) products will be selected by HHS for individuals purchasing health insurance coverage in the ACA marketplaces through plan year 2025 and in 2025, eliminated the “donut hole” under the Medicare Part D Drug Price Negotiation Program. Products subject to the Medicare Drug Price Negotiation Program are expected to experience a significant reduction in reimbursement from the Medicare program on a per unit basis. AUSTEDO and creates a new, permanent cap on beneficiary out-of-pocket spending for Part D drugs, in addition to a newly established manufacturer discount program. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, AUSTEDO XR, marketed by Teva Pharmaceuticals Industries, were selected for the initial years. HHS has issued and updated and will continue to issue and update guidance as these programs are implemented. These provisions took effect progressively beginning in 2023. On August 15, 2024, HHS announced the negotiated prices of the first 10 drugs that were subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. On January 17, 2025, HHS announced its selection of fifteen additional drugs covered under Part D for negotiation Drug Negotiation Program in 2025 (for initial price applicability year 2027). Certain high-expenditure Part B 2027) and Part D drugs/biologics will be selected CMS has announced a negotiated maximum fair price (MFP) for negotiation in 2026 (for initial price applicability year 2028) these products that is lower than their pre-negotiation prices. Lower negotiated prices for AUSTEDO and annually thereafter. While the Medicare drug price negotiation program targets high-expenditure drugs/biologics that have been AUSTEDO XR may increase competitive pressures on the market for several years without generic or biosimilar competition, we were notified in January 2025 that INGREZZA qualifies for the small biotech exception, which provides an exemption from selection until 2027 (for initial price applicability year 2029, pursuant to which negotiated INGREZZA, including heightened pricing would go into effect, if selected). pressure and potential adverse effects on formulary coverage.
Paragraph 179 · 42% changed Every version of it
Prior to the IRA’s enactment, the The most significant recent prior revisions to federal legislation impacting law governing the pharmaceutical industry and prescription drug pricing occurred in March 2010, when the ACA was signed into law. The ACA This law was intended to broaden access to health insurance and reduce by reducing the number of uninsured individuals, reduce persons, reducing or constrain constraining the growth of healthcare spending, enhance enhancing remedies against fraud and abuse, add adding transparency requirements for the healthcare and health insurance industries, impose imposing taxes and fees on the health industry and impose imposing additional health policy reforms. Congress is considering proposed legislation intended to further reduce healthcare costs with alternatives to replace the expiring ACA subsidies. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in the ACA marketplaces through plan year 2025 and eliminated the “donut hole” under the Medicare Part D program in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost to $2,000 through a newly established manufacturer discount program.
Paragraph 261 · 41% changed Every version of it
In the ordinary course of business, we may transfer personal data from Europe and other jurisdictions to the U.S. or other countries. Certain jurisdictions have enacted data localization laws and cross-border personal data transfers laws. For example, countries in the EEA and the UK have significantly restricted the transfer of personal data to the U.S. and other countries, whose privacy laws it generally believes are inadequate. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the U.S. in compliance with law, such as the EEA standard contractual clauses, the UK’s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers for to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the U.S. If we cannot implement a valid compliance mechanism for cross-border personal data transfers or if the requirements for a legally-compliant transfer are too onerous, we may face increased exposure to regulatory actions, substantial fines and injunctions against processing or transferring personal data from Europe or elsewhere. The inability to import personal data to the U.S. may significantly and negatively impact our business operations, including by limiting our ability to conduct clinical trial activities in Europe and elsewhere; limiting our ability to collaborate with parties subject to European and other data protection laws or requiring us to increase our personal data processing capabilities in Europe and/or elsewhere at significant expense. Other jurisdictions may adopt or have already adopted similarly stringent interpretations of their data localization and cross-border data transfer laws. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the U.S., are subject to increased scrutiny from regulators, individual litigants, and activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers out of Europe for allegedly violating the GDPR’s cross-border data transfer limitations.
Paragraph 268 · 40% changed Every version of it
Although we endeavor to comply with all applicable data privacy and security obligations, we may at times fail (or be perceived to have failed) to do so. Moreover, despite our efforts, our personnel or third-parties upon whom we rely may fail to comply such obligations that impacts our compliance posture. If we fail, or are perceived to have failed, to address or comply with data privacy and security obligations, we could face significant consequences. These consequences may include, but are not limited to, government enforcement actions, litigation (including class claims), additional reporting requirements and/or oversight, bans on processing personal data, imprisonment of company officials, and orders to destroy or not use personal data. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, financial condition or results of operations.
Paragraph 162 · 38% changed Every version of it
•disruptions caused by geopolitical and macroeconomic developments, man-made or natural disasters, public health pandemics or epidemics, armed conflicts, trade restrictions, tariffs, including protectionist or retaliatory measures taken by the U.S. or other countries, the recent shutdown of the U.S. federal government and the resulting effects on its regulatory agencies, or other business interruptions; and
Paragraph 108 · 37% changed Every version of it
We have in the past utilized, and intend to continue to utilize, third-party manufacturers to produce the drug compounds we use in our clinical trials and for the commercialization of our products. We have limited experience in manufacturing products for commercial purposes and do not currently have any manufacturing facilities. Establishing internal commercial manufacturing capabilities would require significant time and resources, and we may not be able to timely or successfully establish such capabilities. Consequently, we depend on, and will continue to depend on, several contract manufacturers for all production of products for development and commercial purposes, including INGREZZA and CRENESSITY. If we are unable to obtain or retain third-party manufacturers, we will not be able to develop or commercialize our products, including INGREZZA and CRENESSITY. The manufacture of our products for clinical trials and commercial purposes is subject to specific FDA and equivalent foreign regulations, including current Good Manufacturing Practice good manufacturing practice (cGMP) regulations. Our third-party manufacturers might not comply with FDA or equivalent foreign regulations relating to manufacturing our products for clinical trials and commercial purposes or other regulatory requirements now or in the future. Our reliance on contract manufacturers also exposes us to the following risks:
Paragraph 211 · 36% changed Every version of it
Any sales of our product once commercialized outside the U.S. will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. Additionally, because of our U.S. and international operations, we are also subject to anti-corruption laws and regulations, in the United States and internationally, including but not limited the U.S. Foreign Corrupt Practices (FCPA), the U.K. Bribery Act 2010, and other applicable anti-bribery and corruption laws. Anti-corruption laws are interpreted broadly and prohibit corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party, or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. The FCPA also imposes accounting standards and requirements on publicly traded U.S. corporations and their foreign affiliates, which are intended to prevent the diversion of corporate funds to the payment of bribes and other improper payments. Recent years have seen substantial increase in the global enforcement of anti-corruption laws. Our operations outside the United States could increase the risk of such violations. Our business is also heavily regulated and involves significant interaction with foreign officials. In many countries outside the U.S., independent clinical investigators conducting our clinical trials and prescribers of our products are employed by government entities, and purchasers themselves can be government entities. As such, our interactions with such investigators, prescribers and purchasers may be subject to regulation under the FCPA, as well as other similar under anti-corruption laws and/or regulations enacted by other countries. Failure to comply with these laws, where applicable, can result in significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal and equivalent foreign healthcare programs, and additional reporting requirements and regulatory oversight, any of which could adversely affect our ability to operate our business and our results of operations.
Paragraph 181 · 33% changed Every version of it
Other significant legislative changes impacting the pharmaceutical industry and prescription drug pricing have been adopted since the ACA was enacted. These changes include include, among others, aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and, due to subsequent legislative amendments to the statute, amendments, including the Infrastructure Investment and Jobs Act and Consolidated Appropriations Act of 2023, Act, will remain in effect until through 2032. The American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, increased the statute of limitations period for the government to recover overpayments to providers from three to five years.

MD&A

58 paragraphs · 8 new · 34 reworded · 6 gone · 10-K Feb 11, 2026 against Feb 10, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 14 · 50% changed
For 2024 2025 compared to 2023, 2024, the increase primarily reflected increased investments to expand our discovery and preclinical programs across therapeutic areas and modalities, including endocrinology and metabolic disease (including obesity) and immunology, and expanding our capabilities in biologics (including peptides and antibodies) and gene therapy and other preclinical development programs. therapy.
Paragraph 41 · 47% changed
For 2024 compared to 2023, cash flows from financing activities also the change reflected a $300.0 million payment to a third-party financial institution to repurchase shares of the Company’s common stock share repurchases under a share repurchase program that was authorized by our Board of Directors in October 2024 and the settlement of the 2024 Notes in full for Repurchase Program, $308.8 million in cash. cash payments to settle the convertible senior notes that matured in May 2024, and increased proceeds from issuances of our common stock.
Paragraph 29 · 44% changed
For 2024 2025 compared to 2023, 2024, the increase in total other expense, net, change primarily reflected $138.4 million of expense recognized in connection prior year charges associated with conversions of the 2024 Notes upon maturity convertible senior notes that matured in May 2024 and periodic fluctuations in the fair values of our equity investments, partially offset by increased interest income on our debt security investments.
Paragraph 17 · 44% changed
Year Ended December 31, (in millions) 2025 2024 2023 2022 Royalty revenue Nxera Pharma UK Limited $ 18.6 15.0 $ 21.2 50.0 $ 22.3 Milestones — Takeda Pharmaceutical Company Limited 37.5 7.5 — Xenon Pharmaceuticals Inc. 7.5 — — 20.0 Collaboration and other 6.1 5.3 5.5 Voyager Therapeutics, Inc. 3.0 11.0 — Other 2.4 3.2 0.8 Total collaboration revenues milestones $ 24.7 65.4 $ 26.5 71.7 $ 47.8 0.8
Paragraph 26 · 43% changed
For 2024 2025 compared to 2023, 2024, the increase primarily reflected continued investment in our commercial organization, including organization (including the recent expansion of our psychiatry and long-term care sales team teams completed in September 2024, pre-launch CRENESSITY activities, increased facility expenses related to our new campus facility, 2024 and CRENESSITY-related headcount and commercial launch activities), partially offset by decreased impairment charges of $14.0 million associated with leased office space that has been our vacated as we continue to occupy our new legacy campus facility. facilities.
Paragraph 11 · 36% changed
For 2024 2025 compared to 2023, 2024, the decrease primarily reflected the progression of the Phase 2 program for direclidine in schizophrenia to late-stage in the fourth quarter of 2024 and lower spend on certain early-stage programs in epilepsy and psychiatry, including the successful completions of the Phase 2 programs for osavampator in MDD and NBI-1117568 in schizophrenia, psychiatry programs, partially offset by increased investments investment in the Phase 2 program for NBI-1070770 in MDD and certain our early-stage muscarinic programs. portfolio and the advancements of NBI‑921355, NBI-1140675, and NBIP-01435 into Phase 1 development.
Paragraph 39 · 36% changed
For 2024 compared to 2023, cash flows from investing activities the change also reflected a $31.3 million equity investment in Voyager. Voyager in 2023.
Paragraph 31 · 34% changed
For 2022, 2025, the effective tax rate varied differed from the federal and state statutory rates primarily due to foreign tax effects, including the impact of global intangible low-taxed income (GILTI), credits generated for research activities and activities, excess tax benefits related to stock-based compensation, certain nondeductible expenses, and state income tax effects including the premium paid on the repurchase of the 2024 Notes fluctuations in 2022. state effective tax rates.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors389 words changed in this paragraph; it is 31% similar to last year's version.
New tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified modified, or applied in a manner that is adverse to us or our customers, which could adversely affect our business and financial condition. Federal laws such as the One Big Beautiful Bill Act (OBBBA), enacted in 2025, the IRA enacted in 2022, the Coronavirus Aid, Relief, and Economic Security Act enacted in 2020, and the Tax Cuts and Jobs Act enacted in 2017, made significant changes to the U.S. tax laws. For example, the Tax Cuts and Jobs Act of 2017, the Coronavirus Aid, Relief, required taxpayers to capitalize and Economic Security Act amortize U.S.-based and the Inflation Reduction Act enacted many significant changes to the U.S. tax laws. Among other changes, the Tax Cuts and Jobs Act eliminated the option to deduct non-U.S. based research and development expenses for tax purposes experimental (R&E) expenditures over five and fifteen years, respectively. The OBBBA restored the deductibility of domestic R&E expenditures in the year incurred for tax years beginning after December 31, 2024, but retained the capitalization and requires taxpayers amortization requirement for foreign R&E expenditures. Future guidance from the Internal Revenue Service and other tax authorities with respect to capitalize any laws may affect us, and subsequently amortize certain aspects of such expenses over five years for research activities conducted in the U.S. and over 15 years for research activities conducted outside the U.S. If the requirement to amortize research and development expenditures is not laws could be repealed or otherwise modified, modified or sunset in future years. In addition, it is uncertain if and to what extent various states will continue conform to have an adverse effect on our federal tax liability. Furthermore, our tax obligations and effective tax rate in the jurisdictions in which we conduct business could increase as a result of international tax developments, including the implementation of the Organization for Economic Co-operation and Development’s (OECD) Base Erosion and Profit Shifting “Two-Pillar” framework, which involves the reallocation of taxing rights in respect of certain multinational enterprises above a fixed profit margin to the jurisdictions in which they carry on business (referred to as Pillar One) and the imposition of a minimum effective corporate tax rate (referred to as Pillar Two). Certain countries in which we conduct business have enacted, or are in the process of enacting, core provisions of the Pillar Two rules. We continue to evaluate and assess the potential impact of these new rules, including on our effective tax rate, and our eligibility to qualify for transition and safe harbor. Any changes in tax laws, including any new tax legislation or initiatives, could not only significantly increase our tax provision, cash tax liabilities, and effective tax rate, but could also have a material impact on the value of our deferred tax assets, result in significant one-time charges and ongoing compliance costs, and increase our future tax expense. laws.

Source: Item 1A, 10-K 0000914475-26-000007 vs Item 1A, 10-K 0000914475-25-000037

Accounting Policies153 words changed in this paragraph; it is 50% similar to last year's version.
For available-for-sale debt securities in an unrealized loss position, we first assess whether we intend to sell, or it is more likely than not that we will be required to sell, the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value through earnings. For available-for-sale debt securities that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.

Source: Item 8, Note 1 – Business Overview and Summary of Significant Accounting Policies, 10-K 0000914475-26-000007 vs Item 8, Note 1 – Business Overview and Summary of Significant Accounting Policies, 10-K 0000914475-25-000037

MD&A73 words changed in this paragraph; it is 39% similar to last year's version.
For 2023 2024 compared to 2022, 2023, the increase primarily reflected increased continued investment in our commercial initiatives, including our branded direct-to-consumer INGREZZA advertising campaign and deployment organization (including the expansion of our expanded salesforce psychiatry and long-term care sales teams completed in April 2022, September 2024 and CRENESSITY-related pre-launch activities), increased payroll and benefits facility-based expenses on higher headcount and increased non-cash stock-based compensation expense primarily driven by a charge related to a change in equity grant agreement terms in 2023. our new campus facility, and impairment charges of $14.0 million associated with our vacated legacy campus facilities.

Source: Item 7, 10-K 0000914475-26-000007 vs Item 7, 10-K 0000914475-25-000037

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of NBIX's Risk Factors and MD&A, 10-K Feb 11, 2026 against 10-K Feb 10, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
Legislators, policymakers, and payors may continue to propose and implement cost-containing measures to keep healthcare costs down. For example, in April 2025, the President issued an executive order that, among other things, directed specified agency heads to develop a Center for Medicare and Medicaid Innovation (CMMI) model that enables the Medicare program to obtain better value for high-cost prescription drugs and biological products. In May 2025, the President issued another executive order directing the administration to take immediate steps to end global freeloading and take additional aggressive action should drug manufacturers fail to offer American consumers the Most-Favored Nation (MFN) price. In December 2025, CMS issued proposed regulations that, if finalized, would create CMMI demonstrations that would institute MFN-level pricing in the Medicare Part D and Part B markets. At present, given that the demonstrations are proposed rules that may or may not be finalized or implemented, there is uncertainty as to how these and other potential legal and regulatory changes may impact our business. However, if implemented, these policies could reduce or limit the prices we are able to charge for our products and product candidates that we may successfully develop and for which we may obtain regulatory approval or the level of reimbursement available for our products from governmental authorities or third-party payors. Further, in January 2026, the President released The Great Healthcare Plan, a proposal which calls on Congress to codify the administration’s 16 MFN drug-pricing agreements with manufacturers and potentially extend MFN pricing to additional manufacturers. In addition, the OBBBA is expected to reduce Medicaid spending and enrollment by implementing work requirements for some beneficiaries, capping state-directed payments, reducing federal funding and limiting provider taxes used to fund the program. The OBBBA also narrows access to the Patient Protection and Affordable Care Act (ACA) marketplace exchange enrollment and declines to extend the ACA enhanced advanced premium tax credits, which expired at the end of 2025. These changes, along with other provisions of the OBBBA, are anticipated to reduce the number of Americans with health insurance. Further, an increasing number of countries use prices for medicinal products established in other countries as “reference prices” to help determine the price of
Read it in 10-K Feb 11, 2026 at sec.gov
AddedRisk Factors
the product in their own territory. Consequently, a downward trend in prices of medicinal products in some countries could contribute to similar downward trends elsewhere, including in the U.S.
Read it in 10-K Feb 11, 2026 at sec.gov
AddedRisk Factors
If any of our product candidates encounters any of these potential problems, we may never successfully market that product candidate. Because we believe our continued growth and success depend in part on our ability to identify (by internal development, in-license or acquisition), develop and ultimately commercialize a steady number of additional product candidates, our failure or perceived failure to achieve that plan could adversely affect our business, results of operations and future growth prospects, and could cause the market price of our common stock to decline.
Read it in 10-K Feb 11, 2026 at sec.gov
AddedRisk Factors
Further, changes in federal policy could affect the geopolitical landscape and could give rise to circumstances that negatively affect our business. The third parties that manufacture our products have manufacturing facilities located in Europe. The U.S. has implemented, and has proposed to further implement, tariffs that may increase the costs of our third-party manufacturers and the expense to us to produce the drug compounds we use in our clinical trials and for the commercialization of our products. If such actions were to materially affect us or our third-party manufacturers, we may not be able to successfully develop our product candidates or commercialize our products.
Read it in 10-K Feb 11, 2026 at sec.gov
AddedRisk Factors
New tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified, or applied in a manner that is adverse to us or our customers, which could adversely affect our business and financial condition. Federal laws such as the One Big Beautiful Bill Act (OBBBA), enacted in 2025, the IRA enacted in 2022, the Coronavirus Aid, Relief, and Economic Security Act enacted in 2020, and the Tax Cuts and Jobs Act enacted in 2017, made significant changes to the U.S. tax laws. For example, the Tax Cuts and Jobs Act required taxpayers to capitalize and amortize U.S.-based and non-U.S. based research and experimental (R&E) expenditures over five and fifteen years, respectively. The OBBBA restored the deductibility of domestic R&E expenditures in the year incurred for tax years beginning after December 31, 2024, but retained the capitalization and amortization requirement for foreign R&E expenditures. Future guidance from the Internal Revenue Service and other tax authorities with respect to any laws may affect us, and certain aspects of such laws could be repealed or modified or sunset in future years. In addition, it is uncertain if and to what extent various states will conform to federal tax laws.
Read it in 10-K Feb 11, 2026 at sec.gov
Show the other 52
AddedRisk Factors
Furthermore, our tax obligations (including the cost of compliance) and effective tax rate in the jurisdictions in which we conduct business could increase as a result of international tax developments, including the implementation of the Organization for Economic Co-operation and Development’s (OECD) Base Erosion and Profit Shifting “Two-Pillar” framework, which involves, among other measures, the imposition of a minimum effective corporate tax rate (referred to as Pillar Two). Certain countries in which we conduct business have enacted, or are in the process of enacting, core provisions of the Pillar Two rules (with further provisions expected to be enacted in the future). Based on our current understanding of the minimum revenue thresholds contained in the Pillar Two proposal, we currently expect to fall within the scope of its rules. The OECD has issued (and is expected to
Read it in 10-K Feb 11, 2026 at sec.gov
AddedRisk Factors
continue to issue further) administrative guidance providing transition and safe harbor rules in relation to the implementation of the Pillar Two proposal. For example, on January 5, 2026, the OECD published details of a proposed “side-by-side” arrangement providing for, among other things, additional safe harbors for multinational groups headquartered in certain qualifying jurisdictions. We continue to evaluate and assess the potential impact of these new rules, including on our effective tax rate, and our eligibility to qualify for any transition relief or safe harbor (including under the proposed “side-by-side” arrangement). Any changes in tax laws, including any new tax laws or initiatives, could not only significantly increase our tax provision, cash tax liabilities, and effective tax rate, but could also have a material impact on the value of our deferred tax assets, result in significant one-time charges and ongoing compliance costs, and increase our future tax expense.
Read it in 10-K Feb 11, 2026 at sec.gov
RemovedRisk Factors
Legislators, policymakers, and payors may continue to propose and implement cost-containing measures to keep healthcare costs down. These measures could include limitations on the prices we would be able to charge for product candidates that we may successfully develop and for which we may obtain regulatory approval or the level of reimbursement available for these products from governmental authorities or third-party payors. Further, an increasing number of countries use prices for medicinal products established in other countries as “reference prices” to help determine the price of the product in their own territory. Consequently, a downward trend in prices of medicinal products in some countries could contribute to similar downward trends elsewhere, including in the U.S.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedRisk Factors
records, provide accurate, timely and reliable reports on our financial and operating results, or otherwise operate our business. Any of these consequences could have an adverse effect on our results of operations and financial condition.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedRisk Factors
On October 11, 2024, Kevin Gorman, Ph.D., retired as the Company's President and Chief Executive Officer and Kyle Gano, Ph.D., formerly our Chief Business Development and Strategy Officer, succeeded Dr. Gorman in the CEO role. Dr. Gano also joined our Board of Directors effective as of October 11, 2024. Dr. Gorman founded Neurocrine in 1992 and has held numerous positions across the Company, including Chief Operating Officer, Chief Business Officer, and Senior Vice President of Business Development, before being appointed CEO in 2008. Dr. Gano was appointed Neurocrine’s Chief Business Development Officer in 2011, and Chief Business Development and Strategy Officer in 2020, and is responsible for all of Neurocrine’s business and corporate development activities. Our Board of Directors worked closely with Dr. Gorman on succession planning and believes Dr. Gano and the senior leadership team are well-positioned to continue to execute our strategy. Although Dr. Gorman will continue to serve on our Board of Directors and provide strategic direction to the Company, this leadership transition may be viewed negatively by investors, our strategic partners, or other stakeholders. Further, if the transition is not managed effectively, it could disrupt our operations and impact our financial condition and results.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedRisk Factors
New tax laws or regulations could be enacted at any time, and existing tax laws or regulations could be interpreted, modified or applied in a manner that is adverse to us or our customers, which could adversely affect our business and financial condition. For example, the Tax Cuts and Jobs Act of 2017, the Coronavirus Aid, Relief, and Economic Security Act and the Inflation Reduction Act enacted many significant changes to the U.S. tax laws. Among other changes, the Tax Cuts and Jobs Act eliminated the option to deduct research and development expenses for tax purposes in the year incurred and requires taxpayers to capitalize and subsequently amortize such expenses over five years for research activities conducted in the U.S. and over 15 years for research activities conducted outside the U.S. If the requirement to amortize research and development expenditures is not repealed or otherwise modified, it will continue to have an adverse effect on our tax liability. Furthermore, our tax obligations and effective tax rate in the jurisdictions in which we conduct business could increase as a result of international tax developments, including the implementation of the Organization for Economic Co-operation and Development’s (OECD) Base Erosion and Profit Shifting “Two-Pillar” framework, which involves the reallocation of taxing rights in respect of certain multinational enterprises above a fixed profit margin to the jurisdictions in which they carry on business (referred to as Pillar One) and the imposition of a minimum effective corporate tax rate (referred to as Pillar Two). Certain countries in which we conduct business have enacted, or are in the process of enacting, core provisions of the Pillar Two rules. We continue to evaluate and assess the potential impact of these new rules, including on our effective tax rate, and our eligibility to qualify for transition and safe harbor. Any changes in tax laws, including any new tax legislation or initiatives, could not only significantly increase our tax provision, cash tax liabilities, and effective tax rate, but could also have a material impact on the value of our deferred tax assets, result in significant one-time charges and ongoing compliance costs, and increase our future tax expense.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedRisk Factors
The implementation of these cost containment measures may prevent us from being able to generate revenue, attain sustained profitability or commercialize our drugs, particularly since the majority of our current revenue is derived from federal healthcare programs, including Medicare and Medicaid.
Read it in 10-K Feb 10, 2025 at sec.gov
RewordedRisk Factors
We Our share repurchases may change from time to time, and we can provide no assurance that this we will repurchase shares of our common stock at favorable prices, in particular amounts, or future share at all, and any repurchases will may not enhance long-term stockholder value, and it may not value or prove to be the best use of our cash.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedRisk Factors
The ability of the FDA or comparable foreign regulatory authorities Patent and Trademark Office and other government agencies to review and approve new products perform their normal business functions, can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of manage user fees, fee programs, and statutory, regulatory, and policy changes. changes (such as reductions in force).
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedRisk Factors
The ability of the FDA or comparable foreign regulatory authorities to review and approve new products can be affected by a variety products, and the ability of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. U.S.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedRisk Factors
In addition, government funding of other government agencies or comparable foreign regulatory authorities on which our operations may rely, including Patent and Trademark Office, the Patent Trial and Appeal Board and those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedRisk Factors
We have continued to invest in our commercial infrastructure and distribution capabilities, infrastructure, including the recent expansion of our psychiatry and long-term care sales teams for INGREZZA in September 2024. which we anticipate to be completed by the end of the first quarter of 2026.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedRisk Factors
Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates. candidates, which could adversely affect our business, results of operations and future growth prospects, and could cause the market price of our common stock to decline.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedRisk Factors
Changes in the FDA, Patent and Trademark Office, other government agencies or comparable foreign regulatory authorities could hinder their ability to hire and retain key leadership and other personnel, prevent delay the development and commercialization of new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedRisk Factors
Our financial results are unpredictable and may fluctuate, for among other reasons, due to seasonality and timing of customer purchases and commercial sales of INGREZZA and CRENESSITY, royalties from out-licensed products, the impact of Medicare Part D coverage, including redesign of the Part D benefit enacted as part of the Inflation Reduction Act, IRA, our achievement of product development objectives and milestones, clinical trial enrollment and expenses, research and development expenses and the timing and nature of contract manufacturing, contract research payments, fluctuations in our effective tax rate, disruptions caused by geopolitical and macroeconomic developments, man-made or natural disasters, public health pandemics or epidemics, armed conflicts, trade restrictions, tariffs, the recent shutdown of the U.S. federal government and the resulting effects on its regulatory agencies, or other business interruptions.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedRisk Factors
Any deficiencies in the design design, implementation, or subsequent upgrades of the ERP system could adversely affect the effectiveness of our internal control over financial reporting or our ability to accurately maintain our books and records, provide accurate, timely and reliable reports on our financial and operating results, or otherwise operate our business.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedRisk Factors
The ACA This law was intended to broaden access to health insurance and reduce by reducing the number of uninsured individuals, reduce persons, reducing or constrain constraining the growth of healthcare spending, enhance enhancing remedies against fraud and abuse, add adding transparency requirements for the healthcare and health insurance industries, impose imposing taxes and fees on the health industry and impose imposing additional health policy reforms.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedRisk Factors
Manufacturers of pharmaceutical products may encounter difficulties in production, such as difficulties with production costs and yields, process controls and validation, quality control and quality assurance, including testing of stability, impurities and impurity levels and other product specifications by validated test methods, compliance with strictly enforced U.S., state and non-U.S. regulations, and disruptions or delays caused by geopolitical and macroeconomic developments, man-made or natural disasters, public health pandemics or epidemics, armed conflicts, trade restrictions, tariffs, the recent shutdown of the U.S. federal government and the resulting effects on its regulatory agencies, or other business interruptions.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedRisk Factors
Certain of the diseases that INGREZZA, CRENESSITY, and our product candidates are being developed to address are in underserved and underdiagnosed populations. populations, and, in the case of CRENESSITY, patients may also be incorrectly coded or misclassified in medical and reimbursement records.
Read it in 10-K Feb 11, 2026 at sec.gov
AddedMD&A
For 2025 compared to 2024, the increase primarily reflected increased net product sales of CRENESSITY, which was launched in the U.S. as a first-in-class FDA-approved treatment of CAH in December 2024, and INGREZZA, driven by record total prescriptions on strong patient demand, partially offset by a lower net price due to new market access investments to support long-term growth.
Read it in 10-K Feb 11, 2026 at sec.gov
AddedMD&A
For 2025 compared to 2024, the increase primarily reflected increased net product sales of INGREZZA and increased royalties payable on net product sales of CRENESSITY. In addition, cost of revenues for 2025 excluded costs that were charged to R&D expense prior to FDA approval of CRENESSITY. As a result, this lower-cost drug product reduced our cost of revenues and improved related product gross margins for 2025. In future periods, we expect to incur a higher cost of revenues that includes the cost of CRENESSITY active pharmaceutical ingredients produced following FDA approval.
Read it in 10-K Feb 11, 2026 at sec.gov
AddedMD&A
For 2025 compared to 2024, the increase primarily reflected higher headcount (including an increase of $22.2 million in non-cash stock-based compensation expense) to support our expanded discovery and preclinical programs across therapeutic areas and modalities, including endocrinology and metabolic disease (including obesity) and immunology, and expanding our capabilities in biologics (including peptides and antibodies) and gene therapy.
Read it in 10-K Feb 11, 2026 at sec.gov
AddedMD&A
For 2025 compared to 2024, the increase primarily reflected increased total net product sales, partially offset by continued investments in our commercial organization (including the expansion of our psychiatry and long-term care sales teams completed in September 2024 and CRENESSITY-related headcount and commercial launch activities) and expanded pre-clinical and clinical portfolio. The increase in accounts receivable was driven by higher total gross product sales. The increase in accounts payable and accrued liabilities was driven primarily by higher revenue-related reserves for discounts and allowances attributed to higher gross product sales combined with expanded formulary access for INGREZZA. In addition, the change in income tax assets and liabilities primarily related to timing of foreign tax expense recognition, partially offset by the federal tax benefit on current income taxes payable from the enactment of the OBBBA.
Read it in 10-K Feb 11, 2026 at sec.gov
AddedMD&A
For 2025 compared to 2024, the change primarily reflected decreased share repurchases under the 2025 Repurchase Program compared to the 2024 Repurchase Program and decreased cash payments associated with the convertible senior notes that matured in May 2024.
Read it in 10-K Feb 11, 2026 at sec.gov
AddedMD&A
In addition to the foregoing future capital requirements, in February 2025, our Board of Directors authorized the 2025 Repurchase Program under which we may repurchase up to $500.0 million of our common stock, subject to market conditions. The 2025 Repurchase Program is in addition to the $300.0 million 2024 Repurchase Program that was announced in October 2024 and completed in February 2025. Under the 2025 Repurchase Program, we repurchased 1.5 million shares on the open market for a cost of $167.7 million during 2025. As of December 31, 2025, we had $332.3 million remaining available for additional repurchases under the 2025 Repurchase Program.
Read it in 10-K Feb 11, 2026 at sec.gov
AddedMD&A
We recognize a tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained upon examination by the relevant taxing authority, based on the technical merits of the position. The tax benefit recognized in our consolidated financial statements for a particular tax position is measured as the largest amount of benefit that is more likely than not to be realized upon settlement with the relevant taxing authority. We reevaluate uncertain tax positions and related unrecognized tax benefits as appropriate for changes in facts and circumstances, including significant changes in tax law, regulations or interpretations, new information obtained during a tax examination, the resolution of tax examinations and appeals, and the expiration of statutes of limitations. We recognize accrued interest and penalties, when appropriate, related to uncertain tax positions in income tax expense. An adverse resolution of one or more uncertain tax positions, or changes in our assessment of the recognition or measurement of such positions, could have a material impact on our results of operations in the period in which the change occurs.
Read it in 10-K Feb 11, 2026 at sec.gov
RemovedMD&A
For 2023 compared to 2022, the decrease primarily reflected decreased expense recognized in connection with development milestones achieved under our collaborations with Nxera, Xenon Pharmaceuticals Inc. (Xenon), and Takeda.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedMD&A
For 2023 compared to 2022, the increase primarily reflected higher headcount and increased non-cash stock-based compensation expense primarily driven by a charge related to a change in equity grant agreement terms in 2023.
Read it in 10-K Feb 10, 2025 at sec.gov
RemovedMD&A
For 2023 compared to 2022, the increase primarily reflected increased investment in our commercial initiatives, including our branded direct-to-consumer INGREZZA advertising campaign and deployment of our expanded salesforce completed in April 2022, and increased payroll and benefits expenses on higher headcount and increased non-cash stock-based compensation expense primarily driven by a charge related to a change in equity grant agreement terms in 2023.
Read it in 10-K Feb 10, 2025 at sec.gov
RewordedMD&A
For 2024 2025 compared to 2023, 2024, the increase primarily reflected continued investment in our commercial organization, including organization (including the recent expansion of our psychiatry and long-term care sales team teams completed in September 2024, pre-launch CRENESSITY activities, increased facility expenses related to our new campus facility, 2024 and CRENESSITY-related headcount and commercial launch activities), partially offset by decreased impairment charges of $14.0 million associated with leased office space that has been our vacated as we continue to occupy our new legacy campus facility. facilities.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedMD&A
For 2022, 2025, the effective tax rate varied differed from the federal and state statutory rates primarily due to foreign tax effects, including the impact of global intangible low-taxed income (GILTI), credits generated for research activities and activities, excess tax benefits related to stock-based compensation, certain nondeductible expenses, and state income tax effects including the premium paid on the repurchase of the 2024 Notes fluctuations in 2022. state effective tax rates.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedMD&A
For 2024 2025 compared to 2023, 2024, the increase in total other expense, net, change primarily reflected $138.4 million of expense recognized in connection prior year charges associated with conversions of the 2024 Notes upon maturity convertible senior notes that matured in May 2024 and periodic fluctuations in the fair values of our equity investments, partially offset by increased interest income on our debt security investments.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedMD&A
For 2024 compared to 2023, the increase primarily reflected continued investment in our commercial organization, including organization (including the recent expansion of our psychiatry and long-term care sales team teams completed in September 2024, 2024 and CRENESSITY-related pre-launch CRENESSITY activities, activities), increased facility facility-based expenses related to our new campus facility, and impairment charges of $14.0 million associated with leased office space that has been our vacated as we continue to occupy our new legacy campus facility. facilities.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedMD&A
For 2024 compared to 2023, the increase in total other expense, net, change primarily reflected $138.4 million of expense recognized in connection associated with conversions of the 2024 Notes upon maturity convertible senior notes that matured in May 2024 and 2024, periodic fluctuations in the fair values of our equity investments, partially offset by and increased interest income on our debt security investments.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedMD&A
For 2024 compared to 2023, the decrease primarily reflected lower spend on certain early-stage programs in epilepsy and psychiatry, psychiatry programs, including the successful completions of the Phase 2 programs for osavampator in MDD and NBI-1117568 direclidine in schizophrenia, partially offset by increased investments in the Phase 2 program for NBI-1070770 in MDD and certain early-stage psychiatry programs and our early-stage muscarinic programs. portfolio.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedMD&A
For 2023 2025 compared to 2022, 2024, the increase primarily reflected increased investments in certain early-stage the Phase 3 programs for osavampator in psychiatry, MDD and direclidine in schizophrenia, partially offset by lower spend on early-stage programs crinecerfont in epilepsy. CAH.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, (in (dollars in millions) 2025 2024 2023 2022 Acquired in-process research and development $ 17.4 $ 12.5 $143.9 $ 143.9 as a % of total revenues 0.6 % 0.5 % 7.6 %
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedMD&A
Periodic fluctuations for all periods presented For 2025 compared to 2024 and 2024 compared to 2023, the changes primarily reflected timing differences related to our the purchases, sales, and maturities of debt security investments and changes in our portfolio-mix.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedMD&A
Research and discovery consists of costs incurred prior to the approval of an investigational new drug application by the applicable regulatory agency. agency, including discovery research and preclinical development activities (such as lead optimization, nonclinical studies, preclinical manufacturing, and toxicology).
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedMD&A
For 2024 compared to 2023, the decrease primarily reflected the impact of decreased ONGENTYS® (opicapone) net product sales of ONGENTYS® (opicapone) and lower decreased ONGENTYS inventory reserves in connection with the termination of our license agreement with BIAL, which became effective in December 2023, partially offset by the impact of increased INGREZZA net product sales. sales of INGREZZA.
Read it in 10-K Feb 11, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, (in millions) 2025 2024 2023 2022 Unrealized (loss) gain on equity investments $ (4.0) $ (37.1) $ 28.4 $ 30.8 Charges associated with convertible senior notes — (138.4) — (70.0) Investment income and other, net 90.3 91.0 52.8 4.1 Total other (expense) income, income (expense), net $ 86.3 $ (84.5) $ 81.2 $ (35.1)
Read it in 10-K Feb 11, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NBIX/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.